A method for reducing heterogeneity of a virus preparation may include generating virus ions from the virus preparation, repeatedly increasing at least one of a temperature and an incubation period at the increased temperature of at least one of the virus preparation and the generated virus ions, measuring mass-to-charge ratios and charge magnitudes of at least some of the generated virus ions at each increase of the at least one of the temperature and the incubation period, determining a mass spectrum at each increase of the at least one of the temperature and the incubation period based on values of the respective mass-to-charge ratios and charge magnitudes, and determining, based on the mass spectrums, optimum ones of the temperature and the incubation period which together minimize, or at least reduce, a heterogeneity of the virus preparation without aggregation of virus capsids in the virus preparation.

A method for reducing heterogeneity of a virus preparation may include generating virus ions from the virus preparation, repeatedly increasing at least one of a temperature and an incubation period at the increased temperature of at least one of the virus preparation and the generated virus ions, measuring mass-to-charge ratios and charge magnitudes of at least some of the generated virus ions at each increase of the at least one of the temperature and the incubation period, determining a mass spectrum at each increase of the at least one of the temperature and the incubation period based on values of the respective mass-to-charge ratios and charge magnitudes, and determining, based on the mass spectrums, optimum ones of the temperature and the incubation period which together minimize, or at least reduce, a heterogeneity of the virus preparation without aggregation of virus capsids in the virus preparation.

Methods for detecting cancer cells, or aggressive cancers, by measuring levels of cardiolipin molecules are provided. Methods of treating identified cancers are likewise provided.

Methods for detecting cancer cells, or aggressive cancers, by measuring levels of cardiolipin molecules are provided. Methods of treating identified cancers are likewise provided.

Described herein are methods for identification of peptides that bind MHC-I molecules from within a starting pool of candidate epitope peptides, using a cell-based genetic immunopeptidomic screen.

Described herein are methods for identification of peptides that bind MHC-I molecules from within a starting pool of candidate epitope peptides, using a cell-based genetic immunopeptidomic screen.

The present disclosure relates, in some embodiments, to isolated nucleic acids (also referred to as cap guides) and methods of use thereof for RNA mapping. The disclosure is based, in part, on guide RNAs that bind to a position that is at least 7 nucleotides downstream of the first nucleotide of an mRNA molecule.

The present disclosure relates, in some embodiments, to isolated nucleic acids (also referred to as cap guides) and methods of use thereof for RNA mapping. The disclosure is based, in part, on guide RNAs that bind to a position that is at least 7 nucleotides downstream of the first nucleotide of an mRNA molecule.

The present disclosure provides methods and devices for early diagnosis of an infection, for example by the COVID-19 virus, and determining a course of action for treatment of the infection.

The present disclosure provides methods and devices for early diagnosis of an infection, for example by the COVID-19 virus, and determining a course of action for treatment of the infection.